arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

IGC Pharma, Inc.

IGC
$0.26 ▲ +0.01 (+2.94%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
16 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

IGC Pharma, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $19.9M
Dividend Yield
Revenue Growth -5.5%
Op. Margin None
ROIC -115.2%
FCF / Share $-0.06
Trailing P/E
Price / Book 3.3x
FCF Yield
Debt / Equity 0.02
info Valuation on last close. End-of-day price, Aug 7, 2026.

16-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.27M
↓ -5.5%
Net Income Profit after all expenses
$-7.12M
↑ +45.2%
Operating Margin Operating profit as % of sales
-168.6%
↓ -85.7%
FCF / Share Free cash flow per share
$-0.06
↑ +29.3%
Long-Term Debt Long-term obligations
$134.00K
↓ -2.2%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns
7
Financial Health
47
Cash Quality
48

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 65 quarters